Literature DB >> 23637378

Systemic lupus erythematosus disease activity index 2000 responder index-50 website.

Zahi Touma, Murray B Urowitz, Dafna D Gladman.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23637378     DOI： 10.3899/jrheum.130030

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  12 in total

1.  Glucocorticoid-induced leucine zipper expression is associated with response to treatment and immunoregulation in systemic lupus erythematosus.

Authors:  Saeed Mohammadi; Mohammad Reza Ebadpour; Sima Sedighi; Mohsen Saeedi; Ali Memarian
Journal:  Clin Rheumatol       Date:  2017-06-10       Impact factor: 2.980

2.  Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus.

Authors:  Yoosuf Ali Ashraf Muhammad Hussenbocus; Ziyi Jin; Wenyou Pan; Lin Liu; Min Wu; Huaixia Hu; Xiang Ding; Hua Wei; Yaohong Zou; Xian Qian; Meimei Wang; Jian Wu; Juan Tao; Jun Tan; Zhanyun Da; Miaojia Zhang; Jing Li; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2022-03-01       Impact factor: 2.980

Review 3.  2022 Systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists.

Authors:  Katarzyna Pawlak-Buś; Piotr Leszczyński
Journal:  Reumatologia       Date:  2022-05-18

4.  Relationship between hyperuricemia and serositis in patients with lupus nephritis.

Authors:  Ping Nie; Liangqian Hu; Bing Li; Yan Lou; Manyu Luo; Yali Wang; Xuehong Lu; Ping Luo
Journal:  Int Urol Nephrol       Date:  2021-05-10       Impact factor: 2.370

5.  A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment.

Authors:  Jennifer C Davies; Emil Carlsson; Angela Midgley; Eve M D Smith; Ian N Bruce; Michael W Beresford; Christian M Hedrich
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

6.  Treatment targets in SLE: remission and low disease activity state.

Authors:  Vera Golder; Michel W P Tsang-A-Sjoe
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

7.  Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment.

Authors:  Jennifer C Davies; Angela Midgley; Emil Carlsson; Sean Donohue; Ian N Bruce; Michael W Beresford; Christian M Hedrich
Journal:  RMD Open       Date:  2020-07

8.  DNMT3B (rs2424913) polymorphism is associated with systemic lupus erythematosus alone and with co-existing periodontitis in a Brazilian population.

Authors:  Larissa Nadine da Silva Dias; Marina de Castro Coêlho; Darlene Camati Persuhn; Isabella Lima Arrais Ribeiro; Eutilia Andrade Medeiros Freire; Naila Francis Paulo de Oliveira; Sabrina Garcia de Aquino
Journal:  J Appl Oral Sci       Date:  2022-04-29       Impact factor: 3.144

9.  Cognitive performance in systemic lupus erythematosus patients: a cross-sectional and longitudinal study.

Authors:  L Langensee; J Mårtensson; A Jönsen; K Zervides; A Bengtsson; J Nystedt; B Cannerfelt; P Nilsson; P Mannfolk; J Lätt; T Rumetshofer; P C Sundgren
Journal:  BMC Rheumatol       Date:  2022-04-20

10.  IL-17 is Aberrantly Overexpressed Among Under-treatment Systemic Lupus Erythematosus Patients.

Authors:  Saeed Mohammadi; Sima Sedighi; Ali Memarian
Journal:  Iran J Pathol       Date:  2019-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.